### Globally altered epigenetic landscape and lagging osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone

3

13 14

15

16 17

21

22

23

24

25

29 30

31 32

33

34

35 36

Pavlo Lutsik<sup>1,18</sup>, Annika Baude<sup>1,18</sup>, Daniela Mancarella<sup>1,2,18</sup>, Simin Öz<sup>1,18</sup>, Alexander Kühn<sup>1,2</sup>,
Reka Toth<sup>1</sup>, Joschka Hey<sup>1,2</sup>, Umut H. Toprak<sup>3,4</sup>, Jinyeong Lim<sup>5</sup>, Viet Ha Nguyen<sup>5</sup>, Chao Jiang<sup>6</sup>,
Anand Mayakonda<sup>1,2</sup>, Mark Hartmann<sup>7</sup>, Felix Rosemann<sup>1</sup>, Kersten Breuer<sup>1</sup>, Dominik
Vonficht<sup>2,12,13</sup>, Florian Grünschläger<sup>2,12,13</sup>, Suman Lee<sup>5</sup>, Maren Kirstin Schuhmacher<sup>8</sup>, Denis
Kusevic<sup>8</sup>, Anna Jauch<sup>9</sup>, Dieter Weichenhan<sup>1</sup>, Jozef Zustin <sup>16</sup>, Matthias Schlesner<sup>4</sup>, Simon
Haas<sup>12,13</sup>, Joo Hyun Park<sup>11</sup>, Yoon Jung Park<sup>11</sup>, Udo Oppermann<sup>6,14</sup>, Albert Jeltsch<sup>8</sup>, Florian
Haller<sup>10</sup>, Jörg Fellenberg<sup>15</sup>, Anders M. Lindroth<sup>5,\*</sup>, Christoph Plass<sup>1,17\*</sup>

### 1112 Affiliations

- Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
- 2. Faculty of Biosciences, Ruprecht-Karls-University of Heidelberg, 69120 Heidelberg, Germany
- Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), 69120
   Heidelberg, Germany
   Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), 69120
  - 4. Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
  - 5. Graduate School of Cancer Science and Policy, Cancer Biomedical Science, National Cancer Center, Goyang-si Gyeonggi-do, 10408, Republic of Korea, Republic of Korea
    - 6. Botnar Research Centre, Oxford NIHR BRC, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK
- Section Translational Cancer Epigenomics, Division of Translational Medical
   Oncology, National Center for Tumor Diseases (NCT) & German Cancer Research Center
   (DKFZ), Heidelberg, Germany
  - 8. Department of Biochemistry, Institute of Biochemistry and Technical Biochemistry, University of Stuttgart, 70049 Stuttgart, Germany
    - 9. Institute of Human Genetics, Ruprecht-Karls-University of Heidelberg, 69120 Heidelberg, Germany
    - 10. Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen- Nürnberg, 91054 Erlangen, Germany
    - Department of Nutritional Science and Food Management, Ewha Womans University, Seoul, 03760, Republic of Korea
- 37 12. Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), 69120
   38 Heidelberg, Germany
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM
   gGmbH, 69120 Heidelberg, Germany
- 41 14. FRIAS- Freiburg Institute of Advanced Studies, University of Freiburg, Freiburg, Germany
- 42 15. Department of Experimental Orthopaedics, Orthopaedic University Hospital Heidelberg,
   43 Ruprecht-Karl University of Heidelberg, 69118 Heidelberg, Germany
- 44 16. Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg,
   45 Germany
- 46 17. German Consortium for Translational Cancer Research (DKTK)
- 47 18. These authors contributed equally

### 48 (\*) Corresponding authors

49 Christoph Plass (c.plass@dkfz.de), Anders Lindroth (lindroth@ncc.re.kr)

#### 50 Abstract

The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, 51 52 leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration. We show 53 that in patient-derived stromal cells H3.3-G34W is incorporated into the chromatin and associates with massive epigenetic alterations on the DNA methylation, chromatin accessibility 54 55 and histone modification level that can be partially recapitulated in an orthogonal cell line system by the introduction of H3.3-G34W. These epigenetic alterations affect mainly 56 57 heterochromatic and bivalent regions and provide possible explanations for the genomic instability as well as the osteolytic phenotype of GCTB. The mutation occurs in differentiating 58 59 mesenchymal stem cells and associates with an impaired osteogenic differentiation. We propose that the observed epigenetic alterations reflect distinct differentiation stages of H3.3 60 WT and H3.3 MUT stromal cells and add to H3.3-G34W associated changes. 61

#### 62 **Important abbreviations**

H3.3-G34W, mutated histone variant; H3.3 MUT, stromal cells expressing H3.3-G34W;
H3.3 WT, stromal cells expressing wildtype H3.3

#### 65 Introduction

The discovery of mutated histone genes in aggressive cancers raised a lot of interest in the 66 cancer research community due to their ability to globally alter the epigenomic landscape (1). 67 68 A frequently mutated histone is the non-canonical histone variant H3.3 (2,3). In contrast to canonical H3.1 and H3.2, the incorporation of histone variant H3.3 is replication-independent 69 70 and its turnover occurs throughout the cell cycle (4). Deposition occurs either via the HIRA 71 chaperone complex at sites of gene activation or through ATRX-DAXX into heterochromatic regions (5) and the silent allele of imprinted genes (6). Mouse embryonic stem cells require 72 73 H3.3 for correct establishment of H3K27me3 patterns at bivalent promoters of developmentally 74 regulated genes (7,8). While two human genes, H3F3A and H3F3B, encode for an identical 75 H3.3 protein, oncogenic mutations occur gene-specifically in different tumor types. Lysine-27-76 to-methionine (H3.3-K27M) and glycine-to-arginine or valine substitution (H3.3-G34R/V) in 77 pediatric gliomas (9), as well as glycine-34-to-tryptophan or leucine (H3.3-G34W/L) 78 substitutions in giant cell tumor of bone (GCTB) (10) have been described, all due to mutations 79 in H3F3A. For H3F3B, mutations leading to a lysine -36-to-methionine (H3.3-K36M) substitution were reported in chondroblastomas (10,11). The molecular consequence of the 80 81 H3.3-K27M mutation is a global loss of the repressive chromatin mark H3K27me3 through 82 inactivation of the PRC2 complex (12-14). Similarly, the H3.3-K36M mutation suppresses the 83 deposition of the H3K36me3 mark by interference with histone methyltransferases NSD2 and 84 SETD2 (11,15). Recent findings suggested reduced levels of H3K36me3 and increased levels of H3K27me3 in cis in HeLa cells overexpressing H3.3-G34W (16). However, the detailed 85 86 effects of this mutant histone variant on the epigenome are yet to be determined and to be 87 analyzed in patients. GCTB, where this mutation was shown as the sole alteration, offers a unique system to study these effects in primary patient material. 88

89 GCTB is a rare locally aggressive bone neoplasm, which typically affects the meta-epiphyseal regions of long bones in young adults (17). These tumors consist of three major cell types: 90 stromal cells originating from mesenchymal stem cells (MSC), multinuclear giant cells and 91 92 mononuclear histiocytic cells (18). The GCTB stromal cells show incidence of H3.3-G34W in 93 more than 90% of cases and display markers of both MSC and pre-osteoblast cell populations 94 (10,19). The neoplastic stromal cell population secretes high levels of the receptor activator of 95 NF-kB ligand (RANKL) and reduced levels of its decoy receptor, osteoprotegerin (OPG), thereby attracting and activating surrounding monocytes. Upon activation, the recruited 96

97 monocytes fuse to form multinucleated giant cells, which resemble osteoclasts and lead to98 massive bone destruction (17).

Here we investigate the effects of H3.3-G34W on global epigenomic patterns in patient samples 99 100 from four different centers. We find epigenetic distortions that contribute to the phenotypes of 101 GCTB, stochastic genomic instability and increased osteolysis. Furthermore, we demonstrate 102 that neoplastic and non-neoplastic GCTB stromal cells represent distinct stages of osteogenic differentiation. Differentiation-related epigenetic differences add to the overall picture of H3.3-103 104 G34W-associated global epigenetic alterations, whereas the differentiation delay is potentially driven by the direct effects of H3.3-G34W. Our findings collectively suggest that the single 105 106 alteration of G34W induces epigenomic changes with implications for the development of 107 stromal cells and the tumorigenic process.

#### 108 **Results**

## H3K36 methylation levels are not changed in H3.3-G34W-expressing stromal cells from GCTB patients

Recent biochemical studies have shown that G34 substitutions in H3.3, including G34W, inhibit the activity of the histone methyltransferase SETD2, which is responsible for H3K36me3, *in cis* (16). We verified these effects in HEK293 cells stably overexpressing H3.3-G34W or wildtype H3.3 as a control and confirmed *in cis* effects on H3.3-G34W K36 trimethylation levels. We did not observe any *in trans* effects on endogenous H3 modifications as found for other mutant histones such as H3-K36M (**Figure S1a**).

117 To specifically test if these biochemical findings apply to patient samples, we obtained access to GCTB biopsies from four different cohorts (Table S1). For the initial characterization of 30 118 119 GCTB samples (Table S1), we performed immunohistochemical analysis with a H3.3-G34Wspecific antibody. Positive staining was observed and validated in 29 of 30 cases (Fig. 1a and 120 121 Fig. S1b). The H3.3-G34W-negative case (unified patient identifier, UPI-13) carried a H3F3A 122 (c.103 104GG>TT) mutation encoding a H3.3-G34L substitution that has already been 123 described for GCTB (10) (Fig. 1b, S1c). We established both, neoplastic, H3.3 G34W-124 expressing (H3.3 MUT) and non-neoplastic, H3.3-G34W negative (H3.3 WT) stromal cell lines 125 (Fig. 1b; Table S1), from primary tissue. Cell type differences were ruled out by flow cytometric analyses which revealed a high expression of MSC markers and low expression of 126 127 hematopoietic markers in both H3.3 WT and H3.3 MUT cell lines, suggesting that both are of

mesenchymal origin (Fig. S1d). In total, we collected 96 tissue samples from 95 different 128 129 GCTB patients from four different cohorts (Table S1). We were able to establish 26 stromal 130 cell lines from 24 different GCTB patients from two cohorts (Fig. 1c). In addition to H3.3 WT 131 cells, we analyzed bone marrow-derived primary MSCs from non-GCTB patients from here on 132 referred to as nontumoral stromal cells (nt-SC) (Table S1). We verified the mutational status 133 of the cells using Sanger resequencing, ultra-deep resequencing on the MiSeq platform or whole-genome sequencing (Table S1, Fig. 1b, S1c, S1e). In addition to the common mutation 134 leading to the G34W alteration in H3.3, whole-genome sequencing of seven patient-derived 135 136 primary H3.3 MUT cell lines (Table S1) did not reveal any recurrent genetic alterations (Fig. 137 S1e). In contrast to other malignancies carrying H3F3A mutations, as for example pediatric 138 glioblastoma with co-occurring mutations in TP53 and ATRX (9,20), and to other bone tumors, 139 e.g. osteosarcoma, GCTB showed an extremely low overall mutation frequency for H3.3 MUT 140 and H3.3 WT cells (Fig. 1d, Fig. S1e). This places GCTB in a unique position to uncover 141 epigenomic alterations linked to H3.3-G34W.

142 To understand how H3.3-G34W exerts its function in tumor cells, we analyzed protein fractions by Western blot and found H3.3-G34W incorporated into chromatin (Fig. S2a). To analyze in 143 144 cis effects of H3.3-G34W in patient derived cells, we used a specific and verified antibody to map H3.3-G34W and identify sites of H3.3-G34W enrichment in two independent patient cell 145 146 lines. We identified high-confidence genomic regions showing H3.3-G34W enrichment (Fig. 147 S2b, c, Table S2) and profiled H3K36me3 along with several other histone modifications using 148 ChIP-mentation. Changes of H3K36me3 or H3K27me3 between H3.3 WT and H3.3 MUT 149 stromal cells at sites of H3.3-G34W enrichment were minute and did not recapitulate the in cis 150 results observed in HEK293 cells (Fig. S2b, c). Furthermore, using Western blot analysis of 151 whole cell lysates we did not reveal any changes in the total amount of K36 methylated histone 152 H3 indicating that the G34W substitution does not affect methylation of K36 on other histones 153 lacking the mutation. (Fig. S2d).



155

#### Figure 1: Initial characterization of GCTB patient samples. 156

a. Immunohistochemical staining of primary GCTB tumor resections with a H3.3-G34W-157 specific antibody (Active Motif) (red). UPI, unified patient identifier. b. Quantification of the 158 mutation at position 103 in the H3F3A gene (c.103G>T) leading to the H3.3 G34W substitution 159 160 in tumor resections and derived stromal cell lines using deep targeted resequencing. VAF, 161 variant allele frequency. c. Overview of GCTB tissues and derived stromal cell lines analyzed within this paper. d. Circos plot of recurrent structural variants in osteosarcoma, H3.3-G34R-162 baring pediatric glioblastoma (PedGBM) and GCTB cohorts based on whole genome 163 sequencing data. Green lines represent translocations, blue lines deletions, red lines 164 duplications, and black lines inversions. The variant recurrences are represented by bar plots. 165 166 The outermost layer represents functional small variants (SNVs and small indels). The middle layer represents copy number variations. The innermost layer represents structural variations. 167 All layers are normalized to the compared cohort size. Osteosarcoma cohort was sub-sampled 168 169 at random to the size of the other two cohorts.

#### 170 The epigenome of GCTB H3.3 MUT cells is globally altered

171 We hypothesized that H3.3-G34W might exert its effects through other unidentified epigenetic mechanisms and screened H3.3 MUT and H3.3 WT cells, as well as a large number of biopsies 172 173 of the four GCTB cohorts, using HumanMethylation450 arrays (89 samples in total). We 174 observed full-range DNA methylation changes of a large number of CpG sites (Fig. 2a). 175 Dimensionality reduction and clustering analysis of the methylation data showed the most 176 pronounced changes between primary patient-derived H3.3 MUT and H3.3 WT cell lines as 177 compared to GCTB biopsies. Most of the primary tumor samples had an intermediate 178 methylome identifying them as mixtures of normal and tumor cells (Fig. 2a, b), as also 179 confirmed by deep resequencing of the H3F3A gene locus of tissue-derived DNA showing 180 lower variant allele frequencies than theoretical 0.5 for a heterozygous mutation (Fig. 1b). This 181 observation prompted us to restrict all our subsequent analyses to H3.3 MUT and H3.3 WT 182 cells in order to obtain a clean view of H3.3-G34W-associated epigenetic alterations in pure 183 cell populations. To further a detailed analysis of the epigenome, we profiled DNA methylation 184 at single CpG resolution using whole genome bisulfite sequencing (WGBS), analyzed chromatin accessibility with the assay for transposase-accessible chromatin using sequencing 185 186 (ATAC-seq) and analyzed global distribution of several histone marks (H3K4me1, H3K4me3, 187 H3K9me3, H3K27me3, H3K27ac, H3K36me3) to investigate their potential redistribution. Global hierarchical clustering proved the H3.3-G34W substitution to be the major determinant 188 of variability in DNA methylation, chromatin accessibility and posttranslational histone 189 190 modifications (H3K27me3, H3K27ac, H3K4me1) with H3.3 MUT and H3.3 WT groups forming separate clusters (Fig. 2c, Fig. S2e). In contrast, other modifications (H3K36me3, 191 192 H3K4me3) did not yield in H3.3 MUT- and H3.3 WT-separating clusters. Since nt-SCs 193 clustered with H3.3 WT cells, we combined all H3.3 wild type cells into a single control group 194 (H3.3 WT) for further analysis.

In order to identify loci with more pronounced epigenetic changes, we used a genome-wide 195 196 approach to stratify the observed differences from all epigenetic layers using the ENCODE 197 functional annotation of the MSC epigenome (21). We observed profound differences in several 198 groups of chromatin states including heterochromatic and Polycomb-repressed states as well as 199 bivalent domains (Fig. 2d). Heterochromatic regions were noticeably hypomethylated while 200 bivalent domains accumulated a whole range of alterations, including gain of DNA 201 methylation, loss of chromatin accessibility, as well as loss of several histone modifications 202 (H3K27me3, H3K4me3 etc). Collectively, we conclude that the epigenome of H3.3 MUT cells shows significant and reproducible differences to that of H3.3 WT stromal cells. 203



204

#### 205 Figure 2: Genome-wide epigenetic distortion in H3.3 MUT cells.

a. HumanMethylation450 profiles of GCTB tumor tissue samples, GCTB stromal cells and 206 healthy nontumoral stromal cells (nt-SC). Heatmap displays 10,000 CpG sites with highest S.D. 207 across all samples. Agglomerative, hierarchical clustering of rows (CpGs) and columns 208 (samples) was performed with average-linkage based on Euclidean distance metric. **b.** Principal 209 component analysis of HumanMethylation450 array-based DNA methylation profiles of GCTB 210 211 tumor tissue, GCTB stromal cells and nontumoral stromal cells (nt-SC). c. Hierarchical clustering with correlation distance of DNA methylation (left), open chromatin (middle) and 212 H3K27me3 profiles (right) in H3.3 WT (blue) and H3.3 MUT (red) cells. Heatmaps represent 213 pairwise Pearson correlation coefficients (r) between respective modification profiles of two 214 cell lines. Dendrograms were obtained with agglomerative hierarchical clustering with 1-r 215 distance and average linkage. Heatmap color codes represent H3F3A mutational status (inner), 216 217 and the cell type (outer), the common legend for all heatmaps is given at the bottom. nt-SCnontumoral stromal cells. UPI, Unified patient identifier. d. Stratification of epigenetic 218 differences using MSC-specific chromatin states as defined by ChromHMM. For DNA 219 220 methylation (WGBS, "DNAm") difference between average methylation levels of all CpGs 221 falling into corresponding states in H3.3 WT and H3.3 MUT cells is presented. For ATAC and ChIP-seq of histone modifications, the difference between average normalized read counts over 222 223 all windows of a state is shown. Mnemonics for the ChromHMM states are defined by Roadmap (TssA, active TSS; TssFlnk, active TSS flanking regions; Tx, transcribed regions; TxFlnk, 224 transcription franking regions; TxWk, weakly transcribed regions; Enh, enhancers; EnhG, 225 226 genic enhancers, ZNF/Rpts; zinc finger genes and repeats; TssBiv, bivalent TSS; BivFlnk, flanking bivalent regions; EnhBiv, bivalent enhancer; ReprPC, Polycomb repressed; 227 ReprPCWk, weak Polycomb repressed; Quies, quiescent). 228

229 DNA hypomethylation in genomic megabase-scale domains indicates defects of

230 *heterochromatin potentially contributing to stochastic genomic rearrangements* 

We first followed up changes associated with loss of DNA methylation. In contrast to the 231 homogeneity of DNA methylation profiles observed within each of the two groups (Fig. S3a), 232 DNA methylation was non-uniformly altered between H3.3 WT and H3.3 MUT cells across 233 234 the entire genome (Fig. 3a). The majority of significantly changed loci showed profound reduction of DNA methylation in H3.3 MUT cells, while a minority was hyper-methylated 235 (Fig.3a, Fig. S3b). Overall, H3.3 MUT cells exhibited a 20% genome-wide reduction of DNA 236 237 methylation (Fig.3b, Fig. S3c). To systematically characterize the abundant DNA methylation 238 changes, we segmented the genome into large methylation domains (LMD I to IV) with sizes >20kb (Fig. S3d, Table S2) using a combination of breakpoint analysis and clustering (see 239 240 Methods for details). The majority of regions (predominantly LMDs III and IV) matched the criteria for partially methylated domains i.e. megabase-scale domains of predominantly 241 242 repressive chromatin with low gene density (22). Each LMD had a distinct level of DNA 243 methylation, a discrete pattern of histone marks and gene density, suggesting different functional roles (Fig. 3c-e). For instance, LMD III showed enrichment of H3K27me3, while 244 245 LMD IV was associated with H3K9me3, suggesting an association with facultative and 246 constitutive heterochromatin (Fig. 3e). Furthermore, LMD III domains were often detected as 247 flanking to LMD IV. LMDs I to IV showed decreasing average methylation levels starting from 248 over 0.75 down to less than 0.25 (Fig. 3c). Lowly methylated LMDs III and IV which could be 249 characterized as heterochromatic (Fig. 3e) showed the most pronounced demethylation comparing H3.3 MUT cells to H3.3 WT cells. We concluded that global epigenetic alterations 250 251 in GCTB are non-uniformly distributed along the genome, and that the most pronounced global 252 changes take place in large-scale domains associated with facultative and constitutive 253 heterochromatin, roughly corresponding to LMDs III and IV.

We next sought to associate hypomethylation with other epigenetic alterations. Consistent with the global loss of DNA methylation, we observed increased chromatin accessibility in the H3.3

MUT cells with approximately 1.5-times more gained than lost differential ATAC-seq peaks 256 (Fig. 3f). ATAC peaks gained in H3.3 MUT cells were overrepresented in the LMDs III and 257 IV (Fig. 3g) indicating a more open state in respective genomic segments. These LMDs also 258 259 showed strong reduction in the heterochromatic histone mark H3K9me3 (Fig. 3h). Examples of changes in different LMDs can be seen in Fig. 3i. The ATAC peaks gained in H3.3 MUT 260 261 showed a significant overlap with repetitive elements such as LINE, SINE and LTR elements which are normally silenced by DNA methylation (Fig. S3e, Table S3). Looking at other 262 263 known repetitive regions, such as centromeres and telomers, we found them to be affected by 264 the genome-wide hypomethylation (Fig. S3f). m-FISH analysis found H3.3 WT cells to have a normal karyotype, while H3.3 MUT cells in contrast displayed different, non-recurrent 265 266 centromeric fusions which could be a potential consequence of the heterochromatin defects 267 described above (Fig. 3j). We conclude that H3.3-G34W associates with heterochromatic 268 defects that potentially contribute to a genomic instability previously described as characteristic for GCTB (23). 269

#### 270 Figure 3: Heterochromatin defects in H3.3 MUT stromal cells (on the next page).

a. Binned scatterplot of DNA methylation profiles from WGBS of H3.3 WT cells versus H3.3 271 272 MUT cells. Hexagon color represents binned density gradient of 1 (blue), 1000 (yellow), and 10<sup>6</sup> (red) points. **b.** Genome-wide mean level of DNA methylation in H3.3 WT (blue) and H3.3 273 274 MUT (red) cells. Points represent individual patients, box-plot bar represents the mean, box the 275 inter-quartile range, whiskers extend from the smallest to the largest value within 1.5 IQR from 276 the lower and upper edges of the box, respectively. The difference is statistically significant  $(p=1.5\cdot10^{-5})$ , two-sample t-test). c. Methylation level distribution at large methylation domains 277 278 (LMDs) in H3.3 WT (blue) and H3.3 MUT (red) cells. Each point represents a single LMD segment. d. Mean gene density of LMDs. RefSeq genes were used and for each segment the 279 number of overlapping genes was divided by its length in Mb. e. Normalized levels of histone 280 281 modifications at LMDs in H3.3 WT cells. Heatmap represents z-scores of average signals 282 across all segments falling into the LMDs calculated using overall mean level and standard deviation across all LMD segments. f. Absolute numbers of ATAC-seq peaks with differential 283 284 chromatin accessibility between H3.3 WT cells and H3.3 MUT cells. "lost" and "gained" refer to peaks showing a decrease (disappearance) or increase (emergence) in H3.3 MUT cells, 285 respectively. g. Stratification of differential chromatin accessibility between H3.3 WT and H3.3 286 MUT cells by overlap with LMDs. Labels "lost" and "gained" differential ATAC peaks as in 287 (f); "genome", distribution of ATAC peaks across the complete genome. h. Changes of histone 288 289 modifications between H3.3 WT and H3.3 MUT stromal cells at LMDs. Heatmap represents 290 difference of average read counts, Z-score-normalized with respect to zero. i. Genomic browser 291 view of a representative 7Mbp region on chromosome 14 (positions 96,000,000–103,000,000) for whole-genome bisulfite sequencing, H3K9me3 ChIP-seq and ATAC-seq. Tracks are shown 292 293 for H3.3 WT (blue) and H3.3 MUT (red) cells. Bottom panel indicates gene locations based on the UCSC default gene track. "lost" and "gained" differential ATAC-seq peaks as in (f). j. 294 295 Visualization of karyotypes using m-FISH in H3.3 WT and H3.3 MUT cells.





## Isogenic cells expressing H3.3-G34W recapitulate DNA methylation changes found in H3.3 MUT stromal cells

299 As H3.3 MUT stromal cells showed the strongest epigenetic differences to H3.3 WT stromal 300 cells on the DNA methylation level, we expect DNA methylation to play a major role in stromal 301 cell transformation leading to GCTB. To verify the observed epigenetic changes to be 302 dependent on H3.3-G34W expression, we aimed to recapitulate the findings in an unrelated cell line system. To this end, we introduced the H3.3-G34W encoding mutation in HeLa cells by 303 304 targeting the endogenous H3F3A locus as earlier described (Fig. S4a) (24). Individual iso-H3.3-305 WT and iso-H3.3-G34W clones were isolated of which four iso-H3.3-WT and iso-H3.3-G34W 306 monoclonal lines and one parental HeLa cell line were subject to HumanMethylationEPIC 307 DNA methylation analysis (Fig. 4a). The iso-H3.3-G34W samples showed similar alterations 308 as found when comparing H3.3 MUT and H3.3 WT stromal cells of GCTB (Fig. 4a-e). 309 Principal component analysis of the most variable methylation probes clustered iso-H3.3-WT 310 clones together while iso-H3.3-G34W clones dispersed off, indicating changes in DNA methylation in iso-H3.3-G34W but not WT isogenic cell lines (Fig. 4a). Similar to primary 311 312 GCTB cells, the largest principal component (PC1, 31% of variance explained) captured widespread hypomethylation in iso-H3.3-G34W accompanied by focal hypermethylation 313 314 events (Fig. 4a). Clustering analysis further enforced the distinct difference between iso-H3.3-315 WT and G34W clones (Fig. 4b). A scatter plot of all probes indicated that iso-H3.3-G34W cells 316 showed predominantly hypomethylation like H3.3 MUT cells from GCTB (Fig. 4c). We found 317 9,047 differentially methylated probes ( $\Delta$  -value>0.2 and FDR<0.05) of which 5,688 (63%) were hypomethylated in iso-H3.3-G34W cells (Fig. 4d). CpG sites that lost methylation were 318 319 more frequently localized to intergenic regions and promoter-proximal exons, while 320 hypermethylated ones were in addition moderately enriched at promoters and depleted at exons 321 (Fig. 4e). To a large extent, this recapitulated the situation in primary GCTB stromal cells and 322 confirmed that the changes in DNA methylation are associated with H3.3-G34W. As a specific 323 example, the *RANKL* locus showed hypomethylation at exon 3, a potential alternative promoter 324 element, (Fig. 4f) which is in line with the methylation differences observed between H3.3 WT 325 and H3.3 MUT stromal cells (Fig. 4g). RANKL signaling has been extensively studied in GCTB (25). The expression of RANKL, a master regulator of osteoclast differentiation (26), 326 327 has been shown to be upregulated in GCTB stromal cells causing an osteolytic phenotype (25). We verified the increased expression of RANKL in H3.3 MUT cells (Fig. 4h, Fig. S4b) and 328 329 additionally observed decreased expression and secretion of its decoy receptor Osteoprotegerin 330 (OPG, TNFRSF11B) (Fig. 4i, Fig. S4 b, c). Similar expression patterns were already described

by us earlier (24). OPG had decreased levels of the active histone marks H3K4me3 and 331 332 H3K27ac potentially indicating a missing activation by a transcription factor (Fig. S4d). One known transcription factor of OPG is Early B-cell Factor 2 (EBF2) (27,28) which is a bivalent 333 334 gene (Fig. S4I) and belongs to key regulators of osteogenic differentiation in mice (29). OPG became downregulated after siRNA mediated EBF2 knockdown, confirming a role of EBF2 in 335 336 OPG expression in stromal cells (Fig. 4j, Fig. S4e). The EBF family is a conserved group of four transcription factors. Our RNA-seq analysis found EBF2 and EBF3 to be differentially 337 338 expressed between H3.3 WT and H3.3 MUT stromal cells (Fig. 4k, Fig. S4f). *EBF3*, previously 339 reported as a tumor suppressor in glioblastoma (30,31), showed reduced expression in H3.3 340 MUT cells whereas EBF2 expression was almost completely lost. We found the EBF2 locus to 341 be hypomethylated with a focal hypermethylation around the promoter region (Fig. 41). Increased H3K9me3 and H3K27me3 levels and decreased levels of H3K27ac supported a 342 343 repressed state of EBF2. Lost ATAC signals in H3.3 MUT cells indicated differentially closed chromatin. These findings link the H3.3 G34W-associated epigenetic dysregulation of EBF2 344 345 expression to the osteolytic phenotype of GCTB.

### Figure 4: DNA methylation differences can be recapitulated in isogenic Hela cells and link epigenetic distortion to the osteolytic phenotype of GCTB (on the next page).

a. Principal component analysis of HumanMethylationEPIC profiles of iso-H3.3-WT and iso-348 H3.3-G34W HeLa cells. b. Methylation levels of top 2000 probes associated with each of the 349 350 first three principal components in iso-H3.3-WT and iso-H3.3-G34W cells. c. Scatter plot of 351 individual CpG probe methylation in iso-H3.3-WT (x-axis) vs. iso-H3.3-G34W (y-axis). Color dots indicate incremental delta means of methylation, with orange representing >0.5 delta-352 mean. d. Fractions of HumanMethylationEPIC probes, differentially methylated between iso-353 H3.3-G34W and iso-H3.3-WT HeLa cells, by direction of DNA methylation change. e. 354 355 Enrichment (positive values) or depletion (negative values) of major gene model features 356 among differentially methylated probes. OR, odds ratio. f. Genome browser snapshot displaying DNA methylation levels of CpGs in the vicinity of the TNFSF11 locus in iso-H3.3-357 WT and iso-H3.3-G4W cells. Points represent methylation values individual CpGs and the lines 358 359 depict LOESS curves with degree 1 and span 0.5. g. Genomic browser view of gene TNFSF11 360 encoding for RANKL. Each lane (dash-separated) represents normalized averaged signals of DNA methylation, the level of H3K4me3, H3K4me, H3K9me3, H3K27ac, H3K27me3, 361 H3K36me3 and ATAC in several replicates of H3.3 WT (lane-wise top) or H3.3 MUT (lane-362 wise bottom) cells. h. Expression levels of RANKL (TNFSF11) in H3.3 WT (blue) H3.3 MUT 363 (red) cells as analyzed by RNA-seq. TPM, transcripts per million. i. Expression levels of OPG 364 (TNFRSF11B) in H3.3 WT (blue) H3.3 MUT (red) cells as analyzed by RNA-seq. TPM. 365 transcripts per million. j. Expression analysis of *EBF2* and OPG (*TNFRSF11B*) by qPCR 48 366 hours after siRNA-mediated knockdown of EBF2 in H3.3 WT cells (UPI-13). Log fold change 367 (LFC) relative to expression in cells transfected with a control siRNA. Each dot represents one 368 replicate. Boxplot bar represents mean, box gives the IQR, whiskers span additional 1.5\*IQR 369 370 below and above the bars. Results showed significance in a one-sample t-test with p-values < 371 0.05. k. Expression levels of all members of the EBF family in H3.3 WT (blue) H3.3 MUT (red) cells as analyzed by RNA-seq. TPM, transcripts per million. I. Genomic browser view of 372 the EBF2 locus. Each lane (dash-separated) represents normalized averaged signals of DNA 373

- methylation, the level of H3K4me3, H3K4me, H3K9me3, H3K27ac, H3K27me3, H3K36me3
- and ATAC in several replicates of H3.3 WT (lane-wise top) or H3.3 MUT (lane-wise bottom)cells.



377

Taken together, we show that the stable introduction of H3.3-G34W into a GCTB unrelated cell line recapitulates the DNA hypomethylation trend seen in GCTB stromal cells. Furthermore, we could detect epigenetic alterations that directly and indirectly affected the expression of key regulators of bone metabolism shedding novel light on the emergence of the osteolytic phenotype in GCTB.

# 383 H3.3 MUT cells exhibits localized changes at bivalent promoters and have a distinct 384 osteogenic differentiation state

385 Besides dominant hypomethylation in heterochromatic regions, we additionally observed 386 profound epigenetic changes at bivalent domains (Fig. 2d), which are well known sites of H3.3 387 deposition (5,32). Changes included gain of DNA methylation which coincide with decreased 388 accessibility, decrease of H3K27me3 and increased levels of H3K36me3 (Fig. 2d). Most 389 promoter-associated ATAC peaks that were lost in H3.3 MUT cells overlapped with bivalent 390 promoters (Fig. S5a). As a consequence of epigenetic disturbance, bivalent genes comprised a 391 significant portion of differentially expressed genes both up- and downregulated in H3.3 MUT cells (Fig. S5b). It was previously reported that comparable epigenetic and transcriptional 392 393 perturbations at bivalent genes occur in H3.3-deficient mouse ESCs (7). Genes with decreased 394 expression in H3.3 MUT were significant enriched in Polycomb-target genes, including several 395 developmental transcription factors (Fig. S5c, Table S4). This was also supported by genomic 396 overlap enrichment analysis of lost ATAC peaks showing strong enrichment at regions where 397 binding of PRC2 components EZH2 and SUZ12 was found in numerous cell lines (Fig. S5d, 398 Table S3). GO analysis of closed regions revealed many categories related to differentiation 399 (Fig. S5e). Impaired differentiation was already suggested for tumor entities harboring 400 mutations in histones including GCTB (15,33). To investigate whether H3.3 WT and H3.3 401 MUT cells differ in their osteogenic differentiation state, we performed a comparison across all 402 genes covered by RNA-seq with those obtained from an in vitro differentiation of MSCs. The 403 expression changes during osteogenic differentiation largely correlated inversely with the 404 expression changes observed between H3.3 WT and H3.3 MUT cells, with anticorrelation 405 increasing from very early to late differentiation stages (Fig. 5a). Accordingly, an overlap of 406 the differentially expressed genes from both experiments showed that the majority of matches 407 were upregulated during differentiation and downregulated in H3.3 MUT cells (Fig. S5f). 408 Examples include insulin growth factor 2 (IGF2) and leptin (LEP) previously implicated in 409 osteogenic differentiation (34,35) (Fig. 5a). A global principal component analysis confirmed 410 a less differentiated state of H3.3 MUT cells resembling MSC in a very early stage of

differentiation and H3.3 WT cells showing an expression profile more similar to MSC in early 411 412 to middle stage of osteogenic differentiation (Fig. 5b). To confirm differences in the osteogenic 413 differentiation state, we stained H3.3 WT and H3.3 MUT stromal cells for the activity of the 414 osteogenic marker alkaline phosphatase (ALP). Most of the H3.3 WT cells exhibited ALP 415 activity whereas only some H3.3 MUT cells showed ALP activity (Fig. 5c). Quantification of 416 ALP activity relative to viability as a surrogate for cell count confirmed reduced ALP activity for H3.3 MUT stromal cells (Fig. 5d). Impaired differentiation of GCTB stromal cells was 417 418 suggested earlier based on the analysis of histological markers (36) and transcriptomic profiling 419 (37). We performed an osteogenic differentiation of H3.3 MUT and H3.3 WT cells from several 420 patients in vitro to analyze the potential of H3.3 MUT and H3.3 WT cells to differentiate. While 421 both H3.3 WT and H3.3 MUT stromal cells showed an increase of ALP activity indicating the 422 potential for osteogenic differentiation (Fig. 5c and d), we noticed that H3.3 MUT stromal cells 423 lagged behind and did not achieve the level of ALP activity reached by H3.3 WT stromal cells 424 (Fig. 5c and d). We conclude that H3.3-G34W associates with changes in bivalent regions and 425 that their deregulation potentially has an effect on osteogenic differentiation. H3.3 WT and H3.3 MUT stromal cells therefore differ in their state of osteogenic differentiation in GCTB 426 427 patients and this difference contributes to the herein found epigenetic alterations (Fig. 5e).



428

429 Figure 5: Impairment of osteogenic differentiation in H3.3 MUT stromal cells

430 **a**. Correlation between differentiation- and H3.3 G34W-associated gene expression changes. For the differentiation log-fold changes (LFC) were calculated between average of profiles 431 from each differentiation timepoint group (very early: 0.5 to 2 hours; early: 4 to 554 16 hours, 432 433 mid: 24 to 168 hours; and at: 336 to 504 hours) and the profiles of MSCs sampled prior to the start of the experiment. Each hexagon reflects density of the underlying data points. Genes with 434 435 most pronounced changes in both data sets are marked. b. Principal component analysis of RNA-Seq data from osteogenic differentiation of MSC and expression profiles of GCTB 436 samples added via a projection onto the subspace spanned by principal components 1 and 2. 437 The sampled differentiation timepoints were grouped as: very early (0.5 to 2 hours), early (4 to 438 16 hours), mid (24 to 168 hours) and late (336 to 504 hours). c. Alkaline phosphatase staining 439 of nt-SC, H3.3 WT and H3.3 MUT cells during osteogenic differentiation. d. Quantification of 440 441 alkaline phosphatase activity relative to the viability as a surrogate for cell count over the time course of 14 days of *in vitro* osteogenic differentiation. e. Model for GCTB tumorigenesis: The 442 H3F3A mutation encoding H3.3-G34W occurs in osteoblastic precursor cells and leads to 443 444 alterations in osteogenic differentiation. Epigenetic differences described between H3.3 WT 445 and H3.3 MUT stromal cells are the result of measuring cells at different differentiation stages and direct effects of the mutated histone. 446

17

#### 447 **Discussion**

Mutant epigenetic regulator proteins, including histones, have been described in multiple cancer 448 types (2). Despite the fact that oncogenic mutations in histories influence the epigenetic 449 450 landscape, deep insight into the mechanistic ramifications to cancer initiation is still incomplete. 451 Several studies investigated the mechanism of how the G34W substitution in histone variant 452 H3.3 affects the epigenetic machinery responsible for its post-translational modifications. To 453 this end, reduced H3K36 methylation and increased H3K27me3 in cis was described in model 454 systems and verified by us in this work (16,38). However, whether these effects can be found 455 in patients and whether epigenetic changes are involved in tumorigenesis of GCTB was not 456 known so far. In this paper, we therefore analyzed GCTB tissue as well as patient-derived 457 primary stromal cells from four different centers to investigate H3.3-G34W-associated 458 epigenetic changes and their contribution to the GCTB neoplasia. The high incidence of H3.3-459 G34W in GCTB in a largely unaltered genomic context leaves GCTB as a suitable system to 460 study histone mutation-driven tumorigenesis.

461 We found that, despite that H3.3-G34W is incorporated into chromatin, its presence did not 462 lead to changes in the global amount of H3K36me2/me3 as shown for other substitutions 463 affecting H3.3 lysine 27 and lysine 36 (11,13,39). This ruled out a possible *in trans* effects of 464 H3.3-G34W on histone posttranslational modifications analyzed in this study. Using ChIP 465 sequencing, we identified high confidence H3.3-G34W enrichment sites in patient cell lines 466 and analyzed common histone marks at these regions. No pronounced differences were found 467 that could recapitulate the *in cis* effects on H3.3 lysine methylation observed in HEK293 cells. 468 The absence of clear-cut *in cis* effects upon chromatin modifications could be explained by an 469 inability to distinguish wild-type and mutant H3.3 in GCTB samples by western blot analysis. 470 In ChIP analysis, nucleosomes of mutant cells could include both, wild-type as well as mutated 471 H3.3 obliterating possible in cis effects. Moreover, antibodies against histone modifications cannot distinguish between H3 variants and the overall small fraction of the mutant H3.3 (25% 472 of overall H3.3) in the total H3 pool makes analysis of H3.3 modifications challenging. 473

We show that H3.3-G34W, the sole recurrent alteration of GCTB, associates with large-scale differences in multiple epigenetic marks. H3.3 MUT stromal cells show heterochromatic defects, specifically reduced genome-wide levels of DNA methylation and gained accessibility at heterochromatic regions which is in line with previous reports on pediatric glioblastomas with the G34R substitution in H3.3 (39). These changes could potentially contribute to the genomic instability described for GCTB (23). We furthermore observed localized changes at
bivalent regions, some of the same sites previously described as targets of H3.3 deposition (5,7).
DNA methylation changes could be recapitulated using an isogenic system verifying effects on
the methylome to be H3.3-G34W-specific. Moreover, we show H3.3-G34W-associated
methylome changes to directly or indirectly affect the expression of the main players of bone
metabolism, RANKL and OPG. These results connect the H3.3-G34W-associated epigenetic
dysregulation to the osteolytic phenotype, a hallmark of GCTB.

486 While the epigenomic differences between H3.3 WT and H3.3 MUT stromal cells can be partially ascribed to direct effects of H3.3-G34W, other alterations observed can be explained 487 488 by the fact that H3.3 MUT and H3.3 WT stromal cells represent distinct differentiation stages. Assuming epigenetic reprogramming during differentiation as demonstrated in recent studies 489 490 (40,41), this could also contribute to the epigenetic differences seen between H3.3 WT and 491 H3.3 MUT cells. While expression profiles from H3.3 MUT cells resemble precursor states of 492 osteoblasts, the H3.3 WT cells resemble more mature osteoblasts, suggesting impaired or 493 delayed differentiation of H3.3 MUT cells as already suggested by (42). A weak differentiation 494 signature is in line with previous reports suggesting that neoplastic GCTB stromal cells are 495 expressing markers of an early osteoblastic differentiation (43). Genes such as insulin growth 496 factor 2 (IGF2) (34), leptin (LEP) and stathmin-like 2 (STMN2), found to be dysregulated in 497 H3.3 MUT stromal cells, were described to play a role in mesenchymal stem cell differentiation 498 and osteoclastogenesis in mice, in promoting bone differentiation (35) and as a marker for 499 osteogenesis (44), respectively. The impairment of differentiation of H3.3 MUT stromal cells 500 could be mediated by H3.3-G34W- associated downregulation or prevention of induction of 501 genes upregulated during osteogenic differentiation through a yet unknown mechanism. 502 Epigenetic repression of bivalent genes and dysregulation of PRC2 targets described in this 503 study could potentially contribute to the observed phenotype. H3.3 MUT stromal cells are still 504 able to undergo osteogenic differentiation, as it was also found in studies not separating H3.3-505 mutant neoplastic from H3.3 -wild-type stromal cells of GCTB tissue (45,46).

Taken together, our results suggest that the molecular mechanism behind H3.3-G34W-induced epigenomic alterations and neoplastic transformation in GCTB is different to the action of other mutant histone variants such as H3.3-K27M and H3.3-K36M, where the mutated amino acid is a direct target for histone modification (11,13,15). This suggests that the H3.3-G34W substitution alters the N-terminal interactome as previously described (24), recruiting novel binders or disrupting interactions with binders. The described DNA methylation changes can be indicative of H3.3-G34W affecting either binding or activity of enzymes writing (DNMTs)

or erasing (TETs) this modification. On the structural side it is known that DNMT3a/b 513 514 recognize H3K36me3 with their PWWP-domains (47,48). The G34W substitution might 515 interfere with binding of DNTM3a/b PWWP preventing proper establishment of DNA 516 methylation patterns. The thereby induced remodeling of the epigenome associated with H3.3-517 G34W, in particular changes at heterochromatic and bivalent regions, could contribute to an 518 impaired osteogenic differentiation and the phenotypes of GCTB: stochastic chromosomal rearrangements and increased RANKL signaling. Precise sequences of molecular events 519 520 leading to these phenotypes will be a matter of further studies.

#### 521 Methods

#### 522 *Patient samples*

523 Biopsies and derived primary cell lines were obtained from patients in the Orthopedic 524 University Hospital, Heidelberg (UHOK), the Korean Cancer Center (KCC), the University 525 Clinic of Leipzig (UKL) and the University Medical Center Hamburg-Eppendorf (UKHE). The 526 complete list of samples used in the study is available in **Table S1**. The use of patient samples 527 and the experiments performed in this study was approved by and in accordance with guidelines 528 and regulations by the Ethics Committees of the University of Heidelberg, University Clinic of 529 Leipzig, University Medical Center Hamburg-Eppendorf, and the National Cancer Center of 530 Korea (IRB NCC2015-0070). All H3.3 WT and H3.3 MUT cells analyzed in the manuscript 531 were obtained from different patients or indicated as relapse samples by addition of .2 to the UPI. 532

#### 533 Isolation of GCTB stromal cells from patient tissue

534 Tumor tissue from surgical resections was mechanically cut into small pieces and digested with 1.5 mg/ml collagenase B (Roche Diagnostics, Mannheim, Germany) at 37°C for 3 h in 535 Dulbecco's Modified Eagle Medium (DMEM) (Lonza GmbH, Wuppertal, Germany) high 536 537 glucose supplemented with 10% fetal calf serum (FCS) (Biochrom, Berlin, Germany), and 538 100 U/ml penicillin/streptomycin (Lonza GmbH). Cells were collected by centrifugation, 539 washed twice in PBS and cultured in DMEM as described above. Twenty-four hours after plating, cells were carefully treated with Trypsin/EDTA (Lonza GmbH) leaving the giant cells 540 541 attached in the culture flask. Detached cells were cultured for further 2 passages to eliminate 542 histiocytes and remaining giant cells.

#### 543 Isolation of nt-SC cell lines from the bone marrow

544 Nt-SCs were isolated from fresh bone marrow samples derived from the iliac crest under the approval of the Ethics Committee of the University of Heidelberg. Bone marrow cells were 545 546 purified on a Ficoll-Paque<sup>™</sup> Plus density gradient (GE Healthcare, München, Germany), 547 washed in PBS and treated with erythrocyte lysis buffer (0.154 M NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 548 0.1 mM EDTA) to remove erythrocytes. The nt-SC-enriched fraction was seeded and cultured 549 in DMEM high-glucose supplemented with 12.5% FCS (Biochrom), 2 mM L-glutamine, 550 100 units/ml penicillin, 100 µg/ml streptomycin (Lonza), 4 ng/ml basic fibroblast growth factor (Merck Chemicals GmbH, Darmstadt, Germany, 50 µM 2-mercaptoethanol and 1% non-551 552 essential amino acids (Invitrogen, Karlsruhe, Germany). After 48 h, cultures were washed with PBS to remove non-adherent material. During expansion, medium was replaced twice a week. 553

#### 554 *Cell line maintenance*

The GCTB stromal and nt-SC cell lines were cultivated in DMEM/F12 no phenol red (Gibco,
Invitrogen, Life Technologies, Paislay, UK) supplemented with 10% FCS (Biochrom, Berlin,
Germany) and 2 ng/µl basic FGF (Biolegend, San Diego, USA) at 37°C and 5% CO<sub>2</sub>. To avoid
contact inhibition, cells were split after reaching maximum 90% of confluency.

#### 559 Isogenic cell lines

560 The establishment of H3.3-GFP isogenic cell lines in HeLa cells utilized the zinc-finger (ZF) 561 targeting methodology as previously described (24). In brief, after transfection with ZF and 562 targeting constructs with electroporation, cells were cultured in media under neomycin 563 selection using G418 for four weeks. Surviving cells were FACS-sorted and individual clones were allowed to propagate. HEK293T were lentivirally-transduced with human H3.3-HA-564 565 3XFLAG constructs in pLVX expression vectors and selected with puromycin. A pLVX-566 AcGFP construct was used as control. Cells were maintained in DMEM (Invitrogen<sup>™</sup> Life 567 Technologies, Carlsbad, USA) supplemented with 10% FCS (Biochrom, Berlin, Germany) and 568 penicillin-streptomycin.

#### 569 Immunohistochemistry

For immunohistochemical detection of the H3.3-G34W mutation formalin fixed paraffin
embedded GCT tissue sections were deparaffinized in Roti-Histol (Carl Roth GmbH,
Karlsruhe, Germany) and rehydrated in isopropanol. Antigen retrieval was performed using

Dako target retrieval solution pH 6 (Dako, Hamburg, Germany) for 5 min at 121°C in a 573 574 pressure cooker. Sections were blocked for 30 min at room temperature using PBS 575 supplemented with 5 % bovine serum albumin (BSA). The primary rabbit anti-H3G34W 576 antibody (Active Motiv, Carlsbad, USA) was diluted 1:1000 in PBS/1% BSA and incubated 577 over night at 4°C. The signal was amplified using the BrightVision +Poly-AP kit (VWR, 578 Darmstadt, Germany) according to the manufacturer's instructions. Samples were 579 counterstained with hematoxylin (Carl Roth GmbH) and mounted using Neo-Mount (Merck, 580 Darmstadt, Germany). All used antibodies are listed in Table S5.

#### 581 Lineage verification by flow-cytometric analysis

582 Stromal cells were harvested by trypsination and transferred to 1,5 ml Eppendorf in PBS. Cells were washed with PBS 2% FCS and centrifuged for 5 min at 250 g at 4°C. The antibody staining 583 584 cocktail was prepared in PBS 2% FCS and cells were stained 20 min at 4°C (all antibodies are 585 specified in the Table S5). Afterwards cells were washed with PBS 2% FCS to remove 586 unbound antibodies and centrifuged at 250 g for 5 min. To exclude dead cells during flow 587 cytometric analysis, propidium iodide was added prior to flow analysis. Data were acquired on 588 a BD FACSAria Fusion (Beckton, Dickinson & Company (BD)) and data were analyzed using 589 FlowJo (BD). Prism (GraphPad Software) was used to generate bar graphs. 590 Hematopoietic/erythroid cells were defined as CD45+ CD235+, CD45-CD235- CD105+ and 591 CD45-CD235-CD90+ cells were defined as mesenchymal cells. Freshly frozen iliac crest bone 592 marrow aspirates from healthy donors were used as healthy controls.

#### 593 OPG expression quantification with enzyme-linked immunosorbent assay (ELISA)

5000 cells were seeded into a 96-well plate and cultivated in 100µl media for two days. ELISA
was performed with the Abcam human Osteoprotegerin ELISA Kit following the
manufacturer's instructions.

#### 597 *Cell titer blue assay*

598 Cells were cultivated in a 96-well plate. 100µl fresh media (DMEM/F12 no phenol red (Gibco,

599 Invitrogen, Life Technologies, Paislay, UK) supplemented with 10% FCS (Biochrom, Berlin,

600 Germany)) were added and supplemented with 20µl CTB reagent from Promega. After 2.5h of

601 cultivation at 37°C Fluorescence was recorded at 560Ex/590Em.

#### 602 siRNA knockdown

603 120.00 cells were seeded into a 6-well plate. After 24 hours, medium was changes and 604 transfection was performed using 1µl Dharmafect1 (Horizon Discovery, <u>Waterbeach, UK</u>) 605 reagent in combination with 2 µl of a 25 µM siRNA SMARTpool of Dharmacon (Horizon 606 Discovery, <u>Waterbeach, UK</u>) targeting EBF2. Cells were harvested 48 hours after transfection.

#### 607 Detection of H3F3A-G34W mutation by mutation-specific PCR

608 Genomic DNA was isolated using the Quick DNA Miniprep kit (Zymo research, Freiburg, 609 Germany) according to the manufacturer's protocol. PCR amplification was performed using 610 H3F3A wild-type and H3F3A-G34W specific primer, respectively. The reaction consisted of 2 U Platinum Taq polymerase (Thermo Fisher Scientific, Dreieich, Germany), 0.6 µl MgCl<sub>2</sub> 611 612 (50 mM), 0.4 µl dNTPs (10 mM each), 0.5 µl of each primer (10 µM) and 100 ng genomic DNA as template in a total volume of 20 µl. Samples were incubated at 94°C for 3 min followed 613 614 by 34 cycles of denaturation at 94°C for 15 s, annealing at 66°C for 20 s and extension at 72°C 615 for 30 s and a final extension step at 72°C for 7 min. PCR products were separated on a 1.6% 616 agarose gel, visualized by Midori Green (Biozym, Hessisch Oldendorf, Germany) and imaged. 617 All primers are listed in **Table S6**.

#### 618 Detection of H3F3A-G34W mutation by Sanger sequencing

619 DNA was extracted using the Quiamp Mini Kit (Qiagen, Hilden, Germany), according to the 620 manufacturer's instructions. The PCR reaction to amplify the mutation spanning H3F3A 621 region consisted of 1U Hot Star Taq polymerase (Thermo Fisher Scientific, Dreieich, Germany), 0.8 µl dNTPs (10 mM each, Fermentas, St. Leon-Rot, Germany), 2 µl of each 622 623 primer (10 µM, Sigma-Aldrich, Taufkirchen, Germany) and 100 ng genomic DNA as template in a total volume of 40 µl. Samples were incubated at 95°C for 15 min followed by 10 cycles 624 625 of denaturation at 94°C for 45 s, annealing at 61-56°C for 30 s (touchdown -0.5°C/cycle) and extension at 72°C for 60 s followed by 25 cycles of denaturation at 94°C for 45s, annealing at 626 627 56°C for 30 s and extension at 72°C for 60 s and a final extension step at 72°C for 10 min. 628 Sequencing was performed by GATC Biotech AG, Konstanz, Germany. All primers are listed 629 in Table S6.

#### 630 Deep targeted resequencing using MiSeq

631 Deep resequencing of *H3F3A* amplicons was performed as earlier described (49). In brief, DNA
632 was extracted using the Qiamp Mini Kit (Qiagen, Hilden, Germany), according to the

manufacturer's instructions. The PCR reaction to amplify the mutation spanning region of the 633 634 H3F3A gene consisted of 0.35U HotStart Q5 polymerase (NEB, Ipswich, USA), 0.6 µl dNTPs (10 mM each, Fermentas, St. Leon-Rot, Germany), 0.3 µl of each primer (10 µM, Sigma-635 636 Aldrich, Taufkirchen, Germany) and 25 ng genomic DNA as template in a total volume of 25 µl. Samples were incubated at 98°C for 1 min followed by 33 cycles of denaturation at 98°C 637 638 for 10 s, annealing at 61°C for 30 s and extension at 72°C for 20 s, and a final extension step at 72°C for 2 min. Primer sequences are listed in Table S6. Primers included a sequence 639 640 complementary to the primers used for library preparation. Samples were separated on a 1.2% 641 agarose gel and DNA was visualized by Ethidium Bromide. Gel extraction was performed using 642 the Gel extraction Kit (Qiagen, Hilden, Germany). Libraries were prepared using 12.5µl NEB 643 Next HF 2x PCR mix (New England Biolabs, USA) in combination with 0.75 µl of 10 µM IDT 644 primers with Nextera handles and TruSeq Unique-Dual Indices (IDT, USA), 0.3 µl 100x Sybr 645 green and 11 µl of DNA (2ng). Amplification was performed for 6 cycles with the following progression: 98°c 30sec, 98°C 10 sec, 62°C 30 sec and 72°C 15 sec. Libraries were pooled and 646 647 sequenced on a single flow-cell lane in a or 300 bp paired-end MiSeq run (Illumina, San Diego, CA, USA). The reads were demultiplexed using custom scripts, aligned to the GRCh37 648 649 assembly using *bwa mem* (v. 0.7.8) (50) with default settings. Base frequencies were read into 650 R and analyzed using package *deepSNV* (v. 1.24.0) (51).

# *Detection of genomic structural variations using multiplex fluorescence in situ hybridization, M-FISH*

653 M-FISH was performed as described in (52). Briefly, seven pools of flow-sorted whole 654 chromosome painting probes were amplified and directly labelled using DEAC-, FITC-, Cy3, TexasRed, and Cy5-conjugated nucleotides or biotin-dUTP and digoxigenin-dUTP, 655 respectively, by degenerative oligonucleotide primed (DOP)-PCR. Prior hybridization, 656 657 metaphase preparations of the H3.3 WT and H3.3 MUT cells were digested with pepsin (0.5 mg/ml; Sigma) in 0.2N HCL (Roth) for 10 min at 37°C, washed in PBS, post-fixed in 1% 658 659 formaldehyde, dehydrated with a degraded ethanol series and air dried. Slides were denatured 660 in 70% formamide/1 x SSC/15% dextran sulfate for 2 min at 72°C. Hybridization mixture 661 consisting of 50% formamide, 2 x SSC, Cot1-DNA, and labeled DNA probes was denatured for 7 min at 75°C, preannealed for 20 min at 37°C, and hybridized to the denatured metaphase 662 preparations. After 48 hours incubation at 37°C slides were washed at room temperature in 2 x 663 SSC, 3x 5 min, followed by 2x 5 min in 0.2% SSC/0.2% Tween-20 at 56°C. For indirect labeled 664 665 probes, a two-step immunofluorescence detection was carried out using biotinylated goat anti avidin followed by streptavidin Laser Pro IR790, and rabbit anti digoxin followed by goat anti
rabbit Cy5.5. Slides were washed in 4 x SSC/0.2% Tween-20, counterstained with 4.6diamidino-2-phenylindole (DAPI) and covered with antifade solution. Images of 20 metaphase
spreads of the H3.3 WT and H3.3 G34W cells were captured for each fluorochrome using
highly specific filter sets (Chroma technology, Brattleboro, VT), and processed using the Leica
MCK software (Leica Microsystems Imaging Solutions, Cambridge, UK), respectively.

#### 672 Chromatin fractionation

673 Cell pellets were resuspended in lysis buffer (10 mM HEPES pH 7.6, 10 mM KCl, 0.05% NP40) with protease inhibitors and incubated on ice for 30 minutes. Samples were centrifuged 674 675 at 13200 rpm at 4°C for 10 min and the supernatant was taken as cytosolic fraction. Leftover 676 pellet was further lysed with low salt buffer (10 mM Tris HCl pH 7.5, 3 mM MgCl<sub>2</sub>) 677 supplemented with 1% Triton X-100 for 15 min on ice and centrifuged at 13200 rpm at 4°C for 678 10 min. Supernatant was taken as nuclear proteins. Leftover pellet was resuspended in 0.2M 679 HCl, incubated on ice for 20 min and centrifuged at 13200 rpm at 4°C for 10 min. The 680 supernatant was neutralized with 1M Tris HCl buffer (pH8) and used as the chromatin fraction.

#### 681 Western blot

Proteins were separated using SDS polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Western blotting using the antibodies listed in the **Table S5**. Chemiluminescence signals were imaged using Amersham Imager 680 (GE, Boston, USA). For the separation of endogenous histone H3 proteins and ectopically-expressed H3.3-HA-3XFLAG in HEK293T, we used 8-16% Mini-PROTEAN® TGX gels (Bio-Rad Laboratories).

#### 687 Differentiation and alkaline phosphatase staining

50.000 cells were seeded in 24-well plates. When confluent medium was changed to osteogenic
differentiation medium: DMEM high Glucose mit L-Glutamin supplemented with 10%FCS,
0.1 μM Dexamethason, 0.17mM Ascorbinsäure-2-phosphat and 10mM β-Glycerophosphat.
Alkaline phosphatase activity was analyzed using BCIP/NBT Alkaline Phosphatase Substrate
Kit (Vector Laboratories, Burlingame, CA, USA) after 1min of 4% PFA fixation.

#### 693 Quantification of ALP activity

25

50.000 cells were seeded in 24-well plates. When confluent media was changed to
differentiation media (compare Differentiation and alkaline phosphatase staining) and the first
measurement was performed. After CTB as described above, wells were PBS washed and
fixated for 60sec with 4% PFA in PBS. After PBS washing 500 μl Alkaline Phosphatase Yellow
(pNpp) Liquid Substrate (System for ELISA, Sigma-Aldrich, USA) was added and incubated
at 37°C for 8 minutes. Absorbance was measured at 405nm.

#### 700 Whole-genome sequencing and analysis

701 Read pairs were mapped to the human reference genome (build 37, version hs37d5), using bwa 702 mem (v. 0.7.8) (50) with minimum base quality threshold set to zero [-T 0] and remaining 703 settings left at default values, followed by coordinate-sorting with *bamsort* (with compression 704 option set to fast REF1) and marking duplicate read pairs with *bammarkduplicates* (with 705 compression option set to best (53)); both are part of *biobambam* package (v.0.0.148) (54). 706 Somatic SNVs were identified with the DKFZ SNV-calling workflow (55). Somatic SNVs and 707 indels in matched tumor normal pairs were identified using the DKFZ core variant calling 708 workflows of the ICGC Pan-cancer Analysis of Whole Genomes (PCAWG) project 709 (https://dockstore.org/containers/quay.io/pancancer/pcawg-dkfz-workflow). Tumor and 710 matched control samples were analyzed by *Platypus* (v. 1.0) (56) to identify indel events. SNVs 711 and indels from all samples were annotated using ANNOVAR (v. 2017Jul16) (53) according to 712 GENCODE gene annotation (v. 19) and overlapped with variants from dbSNP10 (build 141) 713 and the 1000 Genomes Project database. Genomic structural rearrangements were detected 714 using SOPHIA (v.34.0) (https://bitbucket.org/utoprak/sophia/src) as described in (57). Briefly, 715 SOPHIA uses supplementary alignments as produced by *bwa mem* as indicators of a possible 716 underlying SV. SV candidates are filtered by comparing them to a background control set of 717 sequencing data obtained using normal blood samples from a background population database 718 of 3261 patients from published TCGA and ICGC studies and both published and unpublished 719 DKFZ studies, sequenced using Illumina HiSeq 2000 (100 bp), 2500 (100 bp) and HiSeq X 720 (151 bp) platforms and aligned uniformly using the same workflow as in this study. An SV 721 candidate is discarded if (i) it has more than 85% of read support from low quality reads; (ii) 722 the second breakpoint of the SV was unmappable in the sample and the first breakpoint was detected in 10 or more background control samples; (iii) an SV with two identified breakpoints 723 724 had one breakpoint present in at least 98 control samples (3% of the control samples); or (iv) both breakpoints have less than 5% read support. Statistics over SVs for 9 samples with 725 726 matched control and integrated variant analysis over all samples were based on SOPHIA calls.

Allele-specific copy-number aberrations were detected using *ACEseq* (v. 1.0) (58). SVs called
by *SOPHIA* were incorporated to improve genome segmentation.

#### 729 ATAC-sequencing and analysis

730 Libraries for ATAC-sequencing were prepared as previously published with modifications (59). Briefly, cells were lysed by 1% NP40 and tagmented at 55°C for 8 minutes in a reaction 731 732 mix with 2.5µl of TDE1 (Nextera Illumina DNAKit), 25µl Tagmentation buffer (Nextera 733 Illumina DNA Kit) and 25µl of lysed cells. Reaction was stopped by adding 10 µl Guanidium 734 (5 M) and samples were purified using Ampure Beads. Libraries were generated using 735 NEBNext High Fidelity PCR Mix and sequenced on the Illumina HiSeq 2000 platform. 736 Sequencing reads were adaptor-trimmed using *cutadapt* (v. 1.10) (60). Genomic alignments 737 were performed against the human reference genome (hg19, NCBI build 37.1) using *Bowtie2* (v. 2.3.0) (61). The non-default parameters "-q 20 -s" were used. PCR duplicates were removed 738 739 by *Picard MarkDuplicates* (v. 1.125). Signal tracks were generated using *deepTools* (v. 2.3.3) 740 (62). Peaks were called using Macs2 (v. 2.1.1.) (63) with the parameters "--nomodel --shift -50 741 --extsize 100 --qvalue 0.01". All peaks were merged to create a common bed file with read 742 counts before differential analysis using *edgeR* (v. 0.3.16) (64). Gene annotations were made 743 using ChIPpeakAnno (v. 3.18.0) (65). Transcription binding motif analysis was performed 744 using *HOMER* (v. 4.9) (66). Motifs with a *P*-value < 0.01 and a ratio of motif to background 745 above 1.1 were defined as significantly enriched.

#### 746 ChIP-sequencing and analysis

747 We used the ChIP-mentation protocol (67) to map the genomic distribution of WT and G34W H3.3, total H3, as well as 6 histone modifications (H3K4me1, H3K4me3, H3K9me3, H3K27ac, 748 749 H3K27me3 and H3K36me3) in a subset of samples (see details in Table S1). To validate the 750 specificity of the H3.3 and H3.3 G34W antibody used for ChIP-Seq analysis, we performed a 751 validation experiment with a Histone code peptide array (JPT, Berlin, Germany) containing 752 short peptides that densely cover most of the known histones and their modifications. We did 753 not observe any significant binding of the G34W-speicifc antibody to H3.3 peptides and a 754 highly specific binding of the H3.3 antibody. Sequence reads were preprocessed using *cutadapt* 755 (v. 1.10) (60) and aligned with *Bowtie2* (v. 2.3.0) (61) with the default command line options. We used deepTools (v. 2.3.3) (62) with non-default options "--binSize 10 --extendReads 400 -756 757 -normalizeTo1x 2451960000 --ignoreForNormalization chrX" to quantify genomic coverage

758 in fixed-size window intervals for meta-plots and heatmaps.

#### 759 Calling of H3.3-G34W enriched regions

We used the Poisson test-based binarization module of the ChromHMM software (v. 1.18) (68)
to generate 200bp windows with statistically significant enrichment of the wild-type H3.3 or
H3.3-G34W signal over a simulated background. Adjacent windows were merged to generate
primary enrichment regions. The regions were filtered against a union of the ENCODE ChIPseq blacklists.

#### 765 Whole-genome bisulfite sequencing and analysis

DNA sequencing libraries were prepared using the TruSeq NanoDNALibrary PrepKit 766 767 (Illumina, San Diego, CA, USA) following the manufacturer's instructions. Paired-end sequencing (2×150 bp) was performed using one lane of a HiSeqX (Illumina) for every sample. 768 769 Basic statistics about the sequencing results is given in Table S1. Raw reads were processed 770 using Trimmomatic (v. 0.36) (69) and aligned against reference sequence of the Genome 771 Research Consortium (v. 37) using *bwa mem* (v. 0.7.8) (50) with default parameters, except for 772 invoking "-T 0". After alignment duplicates were marked by applying *Picard MarkDuplicates* 773 (v. 1.125). Methylation calling was performed with MethylDackel (v. 0.3.0). Coverage filtering 774 still missing). BSmooth was used (v. 1.4.0) with default parameters to smooth the methylation 775 profiles in all samples (70). We then used we DSS (v. 2.27.0) (71) to call DMRs for pairwise 776 comparison between H3.3 WT and H3.3 MUT cells. Regions with at least 3 CpGs, a minimum 777 length of 50bp and a Benjamin-Hochberg corrected P value < 0.05 were selected. All DMRs 778 were filtered requiring a minimal mean methylation-value difference of 0.1.

#### 779 HumanMethylation450 and HumanMethylationEPIC analysis

Methylation analysis using HumanMethylation450 arrays was performed by the Genomics and Proteomics Core Facility according to the manufacturer's instructions. Profiling of isogenic HeLa cell lines with HumanMethylationEPIC arrays was conducted at Korean Cancer Center according to the manufacturer's instructions. Unnormalized signals (IDAT files) were loaded into R using RnBeads software (v. 2.2.0) (72) and subjected to preprocessing with default option settings. 10,000 sites most variable across all samples were used for both, Principal Component Analysis and clustering analysis, visualized as a heatmap.

#### 787 RNA-sequencing and analysis

788 Poly-A RNA sequencing of GCTB samples was performed according to the standard 789 protocol published elsewhere (73). In brief, total RNA was prepared for each cell line by 790 using the RNAeasy Mini kit (Qiagen, Hilden, Germany) and library preparation was done using TruSeq Stranded mRNA Kit (Illumina), according the manufacturer's instruction. 791 792 Paired-end 125bp sequencing runs were performed on Illumina Hiseq2000 v4 machines. Raw 793 sequence reads were preprocessed using *cutadapt* (v. 1.10) (60) to remove sequencing primers and adapters. Reads were aligned to the GRCh37 human reference genome with 794 HISAT2 (v. 2.0.4) (74) with additional non-default parameters "--max-intronlen 20000 --no-795 796 unal --dta". Transcripts were assembled and quantified with StringTie (v. 1.3.3) (75) with the GRCh37 transcript database. Differential expression analysis was performed using 797 798 DeSeq2 (v. 1.18.1) (76). Genes were called differentially expressed at FDR 0.05 and the 799 absolute log-fold difference of greater or equal to one. To compare expression with the data 800 from all TCGA cohorts, the raw data was alternatively quantified with kallisto 801 (v. 0.43.1) (77), and log2-transformed counts were combined with identically processed data 802 downloaded from UCSC Xena portal.

#### 803 RNA-Seq of the differentiation samples

804 RNA-seq of the MSC differentiation samples was performed according to the following 805 protocol. 50,000 cells were seeded in 6-well plates in maintenance medium: MesenPRO-RS™ 806 (Thermo Fisher Scientific, Massachusetts, USA). After 3 days, medium was replaced with 807 osteogenic differentiation medium: DMEM high glucose supplemented with 10% FBS, 1x non-808 essential amino acids (NEAA), 2mM L-glutamine, 0.28mM ascorbic acid, 10 mM ß 809 glycerophosphate, and 10 nM dexamethasone (Sigma-Aldrich, USA). At each time-point: 0, 810 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 125, 168, 336, 504 (hrs) during osteogenesis, total RNA was isolated using TRIzol (Invitrogen<sup>™</sup> Life Technologies, Carlsbad, USA) with the Direct-811 812 zol RNA kit (ZymoResearch, USA) according to the manufacturer's instruction. RNA-seq library preparation was carried out using the NEBNext Poly(A) mRNA Magnetic Isolation 813 814 Module and NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England 815 Biolabs, USA) according to the manufacturer's instruction. The quantity and quality of the 816 cDNA library were assessed using the Agilent 2200 tapestation (Agilent Technologies, Santa Clara, USA). Paired-end sequencing of the pooled library was carried out using the Illumina 817 NextSeq 500 v2 kit (Illumina, San Diego, USA) according to the manufacturer's instruction. 818

819 *qRT-PCR expression analysis* 

820 Total RNA was extracted using the RNeasy Mini kit (Qiagen, Hilden, Germany). cDNA was 821 synthesized using random hexamers (Qiagen, Hilden, Germany), and Superscript III Reverse 822 Transcriptase (Invitrogen, Life Technologies, Paislay, UK) according to the manufacturer's 823 instructions. qPCR mixture consisted of 3.5µl Light Cycler 480 Probe master (Roche 824 Diagnostics, Mannheim, Germany) 1 µl 10 µM Primer mix (Sigma-Aldrich, Taufkirchen, 825 Germany) and 0.05µl UPL probe (Roche Diagnostics, Mannheim, Germany). 2.5 µl of a 1:10 dilution of cDNA served as template. Expression analysis was performed on the LightCycler 826 827 480-2 (Roche) system with the following progression: 10 min 95°C and 45 cycles of 10 s 95°C, 828 20 s 55°C, 1 s 72°C. Alternative to the UPL system, Sybr green qPCR was performed in a total 829 volume of 10 µl including 5µl Prima Quant Mix (Steinbrenner, Wiesenbach, Germany), 0.6 µl 830 Primermix (10 µM each, Sigma-Aldrich) and 2 µl of 1:10 dilution of the template cDNA. Samples were incubated at 95°C for 15 min and 15 s at 95°C, 30 s at 55°C and 10 s at 72°C for 831 832 45 cycles. Target gene expression was normalized to the housekeeping gene GAPDH using the  $\Delta$ CT method (relative expression is equal to 2<sup>- $\Delta$ CT</sup>). All used primers are listed in **Table S6**. 833

#### 834 Targeted DNA methylation analysis using MassARRAY

Bisulfite treatment was performed with the EZ DNA Methylation Kit from Zymo Research following the manufacturer's protocol. PCR was performed with primers listed in **Table S6** using the Qiagen HotStar Taq (Qiagen, Hilden, Germany). The Shrimp alkaline phosphatase step and in vitro transcription were performed with the EpiTYPER Reagent Set from Agena Bioscience following the manufacturer's protocol. Analyses were performed on the Sequenom Platform (Agena Bioscience, San Diego, USA).

#### 841 Gene and genomic feature annotations

842 Unless specified otherwise, Ensembl transcript and gene annotations were used for the GRCh37 843 assembly (build 87). List of bivalent genes in H3.3 WT was compiled by overlapping the 844 consensus H3.3 WT peaks of H3K27me3 and H3K4me3 within 2kb from a RefSeq TSS. A consensus list of bivalent genes in human ESCs was obtained from (78). A list of PRC2 target 845 846 genes was found in (79). A comprehensive list of imprinted genes was obtained from (80). 847 Replication timing domains for the annotation of LMDs originates from Repli-Seq data of (81), 848 processed and publicly deposited by RepliScan package (82). MSC-specific chromatin states 849 were taken from the 15-state ChromHMM model (68) for bone-marrow derived MSCs 850 generated by the Roadmap Epigenomics consortium (21) (sample E026).

#### 851 Identification of large-scale methylation domains

DNA methylation data was summarized in 20 kb tiling windows to eliminate the small-scale variability (e.g. related to CpG islands). The changepoints were then called using R package *changepoint* (v. 2.2.2). DNA methylation data was summarized in the obtained segments and the latter were clustered using standard hierarchical clustering resulting in 6 stable clusters. After clustering adjacent segments that belonged to the same cluster were merged. Two smallest clusters were removed since one contained less then 10 segments and the other one exclusively Y-chromosome segments.

#### 859 Genomic overlap enrichment analysis

860 We tested the significance of overlap of differential ATAC-seq peaks, H3.3 G34W 861 incorporation regions and other regions of interest with publicly available genomic annotations 862 using LOLA (v. 1.8.0) (83). In the case of ATAC peaks a union of all called peaks in H3.3 WT 863 and H3.3 MUT was used as background to test enrichments at H3.3 G34W gained and lost peaks relative to each other. For H3.3 WT and G34W enrichment regions the background set 864 865 consisted of regions called for wild-type H3.3 in H3.3 WT and H3.3 MUT groups, as well as the H3.3-G34W regions. We used the LOLA core database for most of the analyses. Enrichment 866 867 of repeat elements was based on a custom LOLA database created using the UCSC Repeat Masker track (<u>http://www.repeatmasker.org</u>). 868

#### 869 Gene set overrepresentation and enrichment analysis

We used gene sets from the Molecular Signatures Database v. 6.2 (MSigDB) (84) to test for the
overrepresentation of DEGs or genes associated with differential ATAC peaks, and the gene
set enrichment analysis (GSEA) of DEGs. Overrepresentation analysis was performed with the
help of R package *GeneOverlap* (v. 1.14.0). GSEA was performed with *fgsea* package (v. 1.4.1)
(85) using 10,000 permutations.

#### 875 Availability of data and code

All raw sequencing data from WGS, WGBS, ATAC-seq, ChIP-seq, RNA-seq and deep targeted
resequencing were obtained from patient samples (therefore restricted) and are being uploaded
to European Genome-Phenome Archive (EGA): EGA: EGAS00001003730. Processed
sequencing data and microarray data are being uploaded to ArrayExpress database (E-MTAB-

- 7184). All presented results were obtained with the use of published and publicly available 880
- 881 software tools introduced in the Methods section.
- 882

#### References 883

- 884 885
- 1. Mohammad F, Helin K. Oncohistones: drivers of pediatric cancers. Genes Dev 2017;31(23-24):2313-24 doi 10.1101/gad.309013.117. 886
- 887 Nacev BA, Feng L, Bagert JD, Lemiesz AE, Gao J, Soshnev AA, et al. The expanding 2. 888 landscape of 'oncohistone' mutations in human cancers. Nature 2019 doi 889 10.1038/s41586-019-1038-1.
- Bennett RL, Bele A, Small EC, Will CM, Nabet B, Oyer JA, et al. A Mutation in Histone 890 3. 891 H2B Represents a New Class of Oncogenic Driver. Cancer Discov 2019;9(10):1438-51 892 doi 10.1158/2159-8290.CD-19-0393.
- Szenker E, Ray-Gallet D, Almouzni G. The double face of the histone variant H3.3. 893 4. 894 Cell Res 2011;21(3):421-34 doi 10.1038/cr.2011.14.
- 895 5. Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, et al. 896 Distinct factors control histone variant H3.3 localization at specific genomic regions. 897 Cell **2010**;140(5):678-91 doi 10.1016/j.cell.2010.01.003.
- 898 6. Voon HP, Wong LH. New players in heterochromatin silencing: histone variant H3.3 899 and the ATRX/DAXX chaperone. Nucleic acids research 2016;44(4):1496-501 doi 900 10.1093/nar/gkw012.
- 901 7. Banaszynski LA, Wen D, Dewell S, Whitcomb SJ, Lin M, Diaz N, et al. Hira-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells. 902 Cell 2013;155(1):107-20 doi 10.1016/j.cell.2013.08.061. 903
- 904 8. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 905 2006;125(2):315-26 doi 10.1016/j.cell.2006.02.041. 906
- 9. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver 907 908 mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. 909 Nature 2012;482(7384):226-31 doi 10.1038/nature10833.
- Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A 910 10. 911 and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. 912 Nature genetics 2013;45(12):1479-82 doi 10.1038/ng.2814.
- 11. Fang D, Gan H, Lee JH, Han J, Wang Z, Riester SM, et al. The histone H3.3K36M 913 914 mutation reprograms the epigenome of chondroblastomas. Science 915 **2016**;352(6291):1344-8 doi 10.1126/science.aae0065.
- Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, et al. The histone 916 12. H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene 917 expression. Genes Dev 2013;27(9):985-90 doi 10.1101/gad.217778.113. 918
- 919 13. Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. 920 Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric 921 Glioblastoma. Science 2013 doi 10.1126/science.1232245.
- Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, et al. Reduced 922 14. 923 H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer cell **2013**;24(5):660-72 924 doi 925 10.1016/j.ccr.2013.10.006.
- Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, et al. Histone H3K36 926 15. mutations promote sarcomagenesis through altered histone methylation landscape. 927 Science 2016;352(6287):844-9 doi 10.1126/science.aac7272. 928

- 929 16. Shi L, Shi J, Shi X, Li W, Wen H. Histone H3.3 G34 Mutations Alter Histone H3K36
  930 and H3K27 Methylation In Cis. J Mol Biol 2018 doi 10.1016/j.jmb.2018.04.014.
- 931 17. Amanatullah DF, Clark TR, Lopez MJ, Borys D, Tamurian RM. Giant cell tumor of bone. Orthopedics 2014;37(2):112-20 doi 10.3928/01477447-20140124-08.
- 18. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of
  bone. J Am Acad Orthop Surg 2013;21(2):118-26 doi 10.5435/JAAOS-21-02-118.
- 935 19. Goldring SR, Roelke MS, Petrison KK, Bhan AK. Human giant cell tumors of bone identification and characterization of cell types. The Journal of clinical investigation
  937 1987;79(2):483-91 doi 10.1172/JCI112838.
- 938 20. International Cancer Genome Consortium PedBrain Tumor P. Recurrent MET fusion
  939 genes represent a drug target in pediatric glioblastoma. Nat Med 2016;22(11):1314-20
  940 doi 10.1038/nm.4204.
- P41 21. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, *et al.*P42 Integrative analysis of 111 reference human epigenomes. Nature 2015;518(7539):317P43 30 doi 10.1038/nature14248.
- 22. Zhou W, Dinh HQ, Ramjan Z, Weisenberger DJ, Nicolet CM, Shen H, *et al.* DNA
  methylation loss in late-replicating domains is linked to mitotic cell division. Nature
  genetics 2018;50(4):591-602 doi 10.1038/s41588-018-0073-4.
- 947 23. Moskovszky L, Szuhai K, Krenacs T, Hogendoorn PC, Szendroi M, Benassi MS, *et al.*948 Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy,
  949 relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer
  950 2009;48(6):468-79 doi 10.1002/gcc.20656.
- 24. Lim J, Park JH, Baude A, Yoo Y, Lee YK, Schmidt CR, *et al.* The histone variant H3.3
  G34W substitution in giant cell tumor of the bone link chromatin and RNA processing.
  Sci Rep 2017;7(1):13459 doi 10.1038/s41598-017-13887-y.
- 954
   25.
   Balke M. Denosumab treatment of giant cell tumour of bone. The Lancet Oncology

   955
   **2013**;14(9):801-2 doi 10.1016/S1470-2045(13)70291-2.
- 956 26. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature
  957 2003;423(6937):337-42 doi 10.1038/nature01658.
- Steslinger M, Folberth S, Dobreva G, Dorn T, Croci L, Erben R, *et al.* EBF2 regulates
  osteoblast-dependent differentiation of osteoclasts. Dev Cell 2005;9(6):757-67 doi
  10.1016/j.devcel.2005.10.009.
- 961 28. Boyce BF, Xing L, Chen D. Osteoprotegerin, the bone protector, is a surprising target
  962 for beta-catenin signaling. Cell Metab 2005;2(6):344-5 doi
  963 10.1016/j.cmet.2005.11.011.
- 964 29. Wolock SL, Krishnan I, Tenen DE, Matkins V, Camacho V, Patel S, *et al.* Mapping
  965 Distinct Bone Marrow Niche Populations and Their Differentiation Paths. Cell Rep
  966 2019;28(2):302-11 e5 doi 10.1016/j.celrep.2019.06.031.
- 30. Zardo G, Tiirikainen MI, Hong C, Misra A, Feuerstein BG, Volik S, *et al.* Integrated
  genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nature
  genetics 2002;32(3):453-8 doi 10.1038/ng1007.
- Shapira SN, Lim HW, Rajakumari S, Sakers AP, Ishibashi J, Harms MJ, *et al.* EBF2
  transcriptionally regulates brown adipogenesis via the histone reader DPF3 and the BAF
  chromatin remodeling complex. Genes Dev 2017;31(7):660-73 doi
  10.1101/gad.294405.116.
- 32. Voon HP, Hughes JR, Rode C, De La Rosa-Velazquez IA, Jenuwein T, Feil R, *et al.*ATRX Plays a Key Role in Maintaining Silencing at Interstitial Heterochromatic Loci and Imprinted Genes. Cell Rep 2015;11(3):405-18 doi 10.1016/j.celrep.2015.03.036.
- 33. Harutyunyan AS, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N, *et al.*H3K27M induces defective chromatin spread of PRC2-mediated repressive

- 979H3K27me2/me3 and is essential for glioma tumorigenesis. Nat Commun9802019;10(1):1262 doi 10.1038/s41467-019-09140-x.
- 34. Hardouin SN, Guo R, Romeo PH, Nagy A, Aubin JE. Impaired mesenchymal stem cell differentiation and osteoclastogenesis in mice deficient for Igf2-P2 transcripts.
  983 Development 2011;138(2):203-13 doi 10.1242/dev.054916.
- 35. Xu JC, Wu GH, Zhou LL, Yang XJ, Liu JT. Leptin improves osteoblast differentiation
  of human bone marrow stroma stem cells. Eur Rev Med Pharmacol Sci
  2016;20(16):3507-13.
- Huang L, Teng XY, Cheng YY, Lee KM, Kumta SM. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone 2004;34(3):393-401 doi 10.1016/j.bone.2003.10.013.
- 37. Lau CP, Kwok JS, Tsui JC, Huang L, Yang KY, Tsui SK, *et al.* Genome-Wide
  Transcriptome Profiling of the Neoplastic Giant Cell Tumor of Bone Stromal Cells by
  RNA Sequencing. J Cell Biochem 2017;118(6):1349-60 doi 10.1002/jcb.25792.
- 38. Zhang Y, Shan C-M, Wang J, Bao K, Tong L, Jia S. Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation. Scientific Reports 2017;7:43906 doi 10.1038/srep43906.
- 39. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, *et al.*Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological
  Subgroups of Glioblastoma. Cancer cell 2012;22(4):425-37 doi
  10.1016/j.ccr.2012.08.024.
- 40. de la Rica L, Rodriguez-Ubreva J, Garcia M, Islam AB, Urquiza JM, Hernando H, *et al.* PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation. Genome Biol 2013;14(9):R99 doi 10.1186/gb-2013-14-9-r99.
- 1004 41. Rauch A, Haakonsson AK, Madsen JGS, Larsen M, Forss I, Madsen MR, *et al.*1005 Osteogenesis depends on commissioning of a network of stem cell transcription factors
  1006 that act as repressors of adipogenesis. Nature genetics 2019 doi 10.1038/s41588-0191007 0359-1.
- Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005;36(9):945-54 doi 10.1016/j.humpath.2005.07.005.
- Murata A, Fujita T, Kawahara N, Tsuchiya H, Tomita K. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005;10(6):581-8 doi 10.1007/s00776-005-1013
  0946-0.
- 1014 44. Chiellini C, Grenningloh G, Cochet O, Scheideler M, Trajanoski Z, Ailhaud G, *et al.*1015 Stathmin-like 2, a developmentally-associated neuronal marker, is expressed and
  1016 modulated during osteogenesis of human mesenchymal stem cells. Biochem Biophys
  1017 Res Commun 2008;374(1):64-8 doi 10.1016/j.bbrc.2008.06.121.
- Liu L, Aleksandrowicz E, Fan P, Schonsiegel F, Zhang Y, Sahr H, *et al.* Enrichment of
  c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by
  cabozantinib. Cell Death Dis 2014;5:e1471 doi 10.1038/cddis.2014.440.
- 46. Wulling M, Delling G, Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol 2003;34(10):983-93 doi 10.1053/s0046-8177(03)00413-1.
- 47. Baubec T, Colombo DF, Wirbelauer C, Schmidt J, Burger L, Krebs AR, *et al.* Genomic
  profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation.
  Nature 2015;520(7546):243-7 doi 10.1038/nature14176.
- 1026 48. Dhayalan A, Rajavelu A, Rathert P, Tamas R, Jurkowska RZ, Ragozin S, *et al.* The
  1027 Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA
  1028 methylation. J Biol Chem 2010;285(34):26114-20 doi 10.1074/jbc.M109.089433.

- 49. Souren NY, Gerdes LA, Kumpfel T, Lutsik P, Klopstock T, Hohlfeld R, et al. 1029 Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically 1030 1031 Discordant for Multiple Sclerosis. Hum Mutat **2016**:37(8):765-75 doi 1032 10.1002/humu.23003.
- 1033 50. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics **2009**;25(14):1754-60 doi 10.1093/bioinformatics/btp324.
- 1035 51. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, *et al.* Reliable
  1036 detection of subclonal single-nucleotide variants in tumour cell populations. Nat
  1037 Commun 2012;3:811 doi 10.1038/ncomms1814.
- 1038 52. Geigl JB, Uhrig S, Speicher MR. Multiplex-fluorescence in situ hybridization for chromosome karyotyping. Nat Protoc 2006;1(3):1172-84 doi 10.1038/nprot.2006.160.
- 1040 53. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research 2010;38(16):e164 doi 10.1093/nar/gkq603.
- 104354.Tischler G, Leonard S. biobambam: tools for read pair collation based algorithms on1044BAM files. Source Code for Biology and Medicine 2014;9(1):13 doi 10.1186/1751-10450473-9-13.
- 1046 55. Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, *et al.* Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature genetics 2013;45(8):927-32 doi 10.1038/ng.2682.
- 1049 56. Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SRF, Consortium WGS, *et al.*1050 Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nature genetics 2014;46(8):912-8 doi 10.1038/ng.3036.
- 1053 57. Sahm F, Toprak UH, Hubschmann D, Kleinheinz K, Buchhalter I, Sill M, *et al.*1054 Meningiomas induced by low-dose radiation carry structural variants of NF2 and a
  1055 distinct mutational signature. Acta Neuropathol 2017;134(1):155-8 doi
  1056 10.1007/s00401-017-1715-9.
- 1057 58. Kleinheinz K, Bludau I, Huebschmann D, Heinold M, Kensche P, Gu Z, *et al.* ACEseq
  1058 allele specific copy number estimation from whole genome sequencing. bioRxiv 2017
  1059 doi 10.1101/210807.
- 1060 59. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods 2013;10(12):1213-8 doi 10.1038/nmeth.2688.
- 106460.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing1065reads. 2011 2011;17(1):3 doi 10.14806/ej.17.1.200.
- 1066 61. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods
  2012;9(4):357-9 doi 10.1038/nmeth.1923.
- 1068 62. Ramirez F, Dundar F, Diehl S, Gruning BA, Manke T. deepTools: a flexible platform
  1069 for exploring deep-sequencing data. Nucleic acids research 2014;42(Web Server
  1070 issue):W187-91 doi 10.1093/nar/gku365.
- 1071 63. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, *et al.* Model-based
  1072 analysis of ChIP-Seq (MACS). Genome Biol 2008;9(9):R137 doi 10.1186/gb-2008-91073 9-r137.
- McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNASeq experiments with respect to biological variation. Nucleic acids research
  2012;40(10):4288-97 doi 10.1093/nar/gks042.
- 107765.Zhu LJ. Integrative analysis of ChIP-chip and ChIP-seq dataset. Methods Mol Biol1078**2013**;1067:105-24 doi 10.1007/978-1-62703-607-8\_8.

- Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations 1079 66. of lineage-determining transcription factors prime cis-regulatory elements required for 1080 1081 macrophage and В cell identities. Mol Cell 2010;38(4):576-89 doi 10.1016/j.molcel.2010.05.004. 1082
- 1083 67. Schmidl C, Rendeiro AF, Sheffield NC, Bock C. ChIPmentation: fast, robust, low-input
  1084 ChIP-seq for histones and transcription factors. Nat Methods 2015;12(10):963-5 doi
  1085 10.1038/nmeth.3542.
- 1086 68. Ernst J, Kellis M. Chromatin-state discovery and genome annotation with ChromHMM.
  1087 Nat Protoc 2017;12(12):2478-92 doi 10.1038/nprot.2017.124.
- 108869.Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina1089sequence data.Bioinformatics109010.1093/bioinformatics/btu170.2014;30(15):2114-20
- 1091 70. Hansen KD, Langmead B, Irizarry RA. BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions. Genome Biol 2012;13(10):R83 doi 10.1186/gb-2012-13-10-r83.
- 109471.Park Y, Wu H. Differential methylation analysis for BS-seq data under general1095experimentaldesign.Bioinformatics2016;32(10):1446-53doi109610.1093/bioinformatics/btw026.
- 1097 72. Assenov Y, Muller F, Lutsik P, Walter J, Lengauer T, Bock C. Comprehensive analysis
  1098 of DNA methylation data with RnBeads. Nat Methods 2014;11(11):1138-40 doi
  1099 10.1038/nmeth.3115.
- Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, *et al.*Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in
  early-onset prostate cancer. Cancer cell 2013;23(2):159-70 doi
  10.1016/j.ccr.2013.01.002.
- 1104 74. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods 2015;12(4):357-60 doi 10.1038/nmeth.3317.
- Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie
  enables improved reconstruction of a transcriptome from RNA-seq reads. Nat
  Biotechnol 2015;33(3):290-5 doi 10.1038/nbt.3122.
- 110976.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for1110RNA-seq data with DESeq2. Genome Biol 2014;15(12):550 doi 10.1186/s13059-014-11110550-8.
- 1112 77. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 2016;34(5):525-7 doi 10.1038/nbt.3519.
- 1114 78. Court F, Arnaud P. An annotated list of bivalent chromatin regions in human ES cells:
  1115 a new tool for cancer epigenetic research. Oncotarget 2017;8(3):4110-24 doi
  10.18632/oncotarget.13746.
- 1117 79. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006;20(9):1123-36 doi 10.1101/gad.381706.
- 1120 80. Skaar DA, Li Y, Bernal AJ, Hoyo C, Murphy SK, Jirtle RL. The human imprintome: regulatory mechanisms, methods of ascertainment, and roles in disease susceptibility.
  1122 ILAR J 2012;53(3-4):341-58 doi 10.1093/ilar.53.3-4.341.
- 1123 81. Hansen RS, Thomas S, Sandstrom R, Canfield TK, Thurman RE, Weaver M, *et al.*1124 Sequencing newly replicated DNA reveals widespread plasticity in human replication
  1125 timing. Proceedings of the National Academy of Sciences of the United States of
  1126 America 2010;107(1):139-44 doi 10.1073/pnas.0912402107.
- 1127 82. Zynda GJ, Song J, Concia L, Wear EE, Hanley-Bowdoin L, Thompson WF, *et al.*1128 Repliscan: a tool for classifying replication timing regions. BMC Bioinformatics
  1129 2017;18(1):362 doi 10.1186/s12859-017-1774-x.

1130 83. Sheffield NC, Bock C. LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor. Bioinformatics 2016;32(4):587-9 doi 10.1093/bioinformatics/btv612.

- 84. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, *et al.*Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proceedings of the National Academy of Sciences of the
  United States of America 2005;102(43):15545-50 doi 10.1073/pnas.0506580102.
- 1137 85. Sergushichev A. An algorithm for fast preranked gene set enrichment analysis using
- 1138 cumulative statistic calculation. bioRxiv **2016** doi 10.1101/060012.

#### 1139 Acknowledgements

- 1140 We acknowledge the Genomics and Proteomics Core Facility of the German Cancer Research
- 1141 Center (head Stephan Wiemann) for their assistance with the high-throughput sequencing, and
- the Omics and Data Management Core Facility (heads Jürgen Eils, Christian Lawerenz and
- 1143 Ivo Buchhalter) for the help with processing and management of the sequencing data. We are
- thankful to Christa Winkelmann (Institute of Pathology, Erlangen) for excellent performance
- 1145 of immunostainings, Cansu Cirzi for the help with ChIP-mentation libraries and Oliver
- 1146 Mücke for his help with MassARRAY. We thank ActiveMotif for providing a novel specific
- antibody against H3.3-G34W, as well as JPT (Pavlo Holenya and Ulf Reimer) for kindly
- 1148 providing a histone peptide array for antibody validation. We thank Stephan Pfister and David
- 1149 Jones for the permission to use PedGBM cohort, and Ana Banito for a thoughtful feedback
- about the manuscript.

### 1151 Author Contributions

C.P. and A.L. supervised the study. F.H., J.Z. and J.F. provided GCTB samples and performed
their initial characterization. A.B., S.Ö., D.M., J.F., A. Jau., A.K., M.H., J.L., M. Schl.,
M.Schuh., D.V., F.G., S.H., V.H.N., S.L., J.H.P., Y.J.P., D.K., C.J., F.R. and D.W. performed
experimental work. P.L., S.Ö., A.M., U.T., R.T., J.H., K.B., C.J., U.O. performed
bioinformatical data analysis and interpretation. P.L., A.B., S.Ö., D.M., A.K., C.P. and A.L.
wrote the manuscript.

#### 1158 **Competing interests' statement**

- 1159 The authors declare no potential conflicts of interest.
- 1160 Requests for materials and other correspondence should be directed to corresponding authors.